Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study

SIMPLE SUMMARY: The management of cardiovascular adverse events in patients with relapsed/refractory multiple myeloma undergoing treatment with carfilzomib can be challenging. Herein, we evaluated the potential cardioprotective effect of daratumumab when administered in combination with carfilzomib...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Stamatelopoulos, Kimon, Makris, Nikolaos, Georgiopoulos, Georgios, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Laina, Ageliki, Eleutherakis-Papaiakovou, Evangelos, Fotiou, Despina, Kanellias, Nikolaos, Malandrakis, Panagiotis, Delialis, Dimitris, Andreadou, Ioanna, Kastritis, Efstathios, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533991/
https://www.ncbi.nlm.nih.gov/pubmed/34680206
http://dx.doi.org/10.3390/cancers13205057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533991/
https://www.ncbi.nlm.nih.gov/pubmed/34680206
http://dx.doi.org/10.3390/cancers13205057

Ejemplares similares